HONYA Medical PTY LTD, Taiwan
Research Article
Efficacy and Safety Evaluation of Intravenous MiSaver Stem Cell Therapy in Recent Acute Myocardial Infarction: A Retrospective Phase IIa Study
Author(s): Kwo Chang Ueng*, Chin Feng Tsai, Chun-Hung Su, Yao Tsung Chuang and Jackson TK Liu
Background: Despite advancements in cardiovascular treatments, Acute Myocardial Infarction (AMI) remains a
significant health challenge. We aimed to explore the potential of stem cell therapy to improve left ventricular
function post-AMI through an open-label, dose-escalating trial. The study aimed to assess the safety and feasibility
of intravenous infusion of MiSaver, a prefabricated product of ABO matched allogeneic umbilical cord blood stem
cells (USC), in patients following recent AMI.
Methods: Participants were enrolled in cohorts of five, receiving escalating dosages of USC (0.5 × 10^7, 1.6 × 10^7,
and 5.0 × 10^7 cells/kg). Infusions were administered 2-5 days post-AMI onset. Due to recruitment challenges during
the COVID-19 pandemic, this retrospective analysis was conducted us.. View More»
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 